CytoVeris Inc., a medical device company focused on intraoperative tissue visualization technologies, has announced the addition of Dr. Fredric Moll, MD as a Strategic Advisor. Dr. Moll is a pioneer in the field of surgical robotics, having founded notable companies such as Auris Health, which was acquired by Johnson & Johnson in 2019. He has also founded companies like Hansen Medical, Restoration Robotics, and Intuitive Surgical, the latter of which is a leader in robotic surgery with their da Vinci system.
With his extensive experience and expertise, Dr. Moll will provide guidance and insight to CytoVeris in driving their AI-powered tissue imaging technology into minimally invasive surgery and robotic applications. The use of robotics in surgery has been revolutionizing healthcare, and with an increasing number of companies entering the surgical robotics market, there is a growing need for advanced features and improved tissue visualization.
CytoVeris is focused on developing AI-powered imaging technology for real-time ex-vivo tissue visualization and identification. Their proprietary Multi-Spectral Tissue Auto-Fluorescence Imaging (MS-TAFI) system, combined with AI-based algorithms, analyzes the biomolecular and morphological characteristics of tissue without the use of dyes or imaging agents. This technology aims to improve surgical decision making, leading to enhanced patient outcomes and reduced repeat procedures.
With Dr. Moll’s guidance, CytoVeris aims to address the growing opportunity for enhanced tissue visualization in robotic surgery. The company sees great potential in the application of robotics in surgery, and they believe that advanced features and technologies will be sought after by surgeons and hospital administrators.
Dr. Moll’s addition as a Strategic Advisor further strengthens CytoVeris’ position in the medical device industry. The company is excited to have him on board, and they believe that his unique qualifications and insights will greatly benefit their development strategy.
Sources:
– CytoVeris Inc.
– PRNewswire